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Hepatocellular  carcinoma  (HCC)  results  in 
>600,000 deaths per year worldwide (Caldwell 
and Park, 2009). Although the major risk fac-
tors have been identified, including infection 
with hepatitis viruses B or C, mechanisms that 
are at work during the development of HCC 
remain poorly understood, hindering the devel-
opment of novel therapeutic approaches (Farazi 
and DePinho, 2006).
The extended retinoblastoma (RB) path-
way  is  comprised  of  p16INK4a  and  p21CIP1 
family members, which inhibit the kinase ac-
tivity  of  Cyclin–Cyclin-dependent  kinase 
(CDK) complexes; these complexes in turn 
normally inactivate the RB protein and its 
two family members p107 and p130 by hy-
perphosphorylation during the G1/S transi-
tion of the cell cycle, thereby activating E2F 
transcription  factors  (Burkhart  and  Sage, 
2008). Accumulating evidence suggests an al-
most universal inactivation of the RB pathway 
in HCC, including by promoter hypermeth-
ylation of the p16INK4a (50% of cases) or 
p15INK4b (15% of cases) genes, and amplifi-
cation  of  the  gene  coding  for  Cyclin  D1 
(30% of cases). Mutations in the RB gene 
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Hepatocellular carcinoma (HCC) is the third cancer killer worldwide with >600,000 deaths 
every year. Although the major risk factors are known, therapeutic options in patients remain 
limited in part because of our incomplete understanding of the cellular and molecular mecha-
nisms influencing HCC development. Evidence indicates that the retinoblastoma (RB) pathway 
is functionally inactivated in most cases of HCC by genetic, epigenetic, and/or viral mecha-
nisms. To investigate the functional relevance of this observation, we inactivated the RB 
pathway in the liver of adult mice by deleting the three members of the Rb (Rb1) gene 
family: Rb, p107, and p130. Rb family triple knockout mice develop liver tumors with histo-
pathological features and gene expression profiles similar to human HCC. In this mouse 
model, cancer initiation is associated with the specific expansion of populations of liver stem/
progenitor cells, indicating that the RB pathway may prevent HCC development by maintain-
ing the quiescence of adult liver progenitor cells. In addition, we show that during tumor 
progression, activation of the Notch pathway via E2F transcription factors serves as a nega-
tive feedback mechanism to slow HCC growth. The level of Notch activity is also able to 
predict survival of HCC patients, suggesting novel means to diagnose and treat HCC.
© 2011 Viatour et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS
Genetic ablation of the Rb gene family in the liver  
of adult mice results in the development of tumors similar 
to human HCC
To model the functional inactivation of the RB pathway found 
in human HCC, we specifically deleted the three Rb family 
genes in the liver of adult mice by performing intrasplenic in-
jection of adenovirus expressing the Cre recombinase (Ad-Cre) 
in conditional TKO (cTKO; Rblox/lox;p130lox/lox;p107/; Viatour 
et al., 2008) adult mice. In this protocol, the adenovirus pre-
dominantly delivers the Cre recombinase to hepatocytes as well 
as nonparenchymal cells in the liver (Fig. S1 A). All of the   
Ad-Cre–infected cTKO mice analyzed and none of the control 
mice infected with Ad-GFP developed multiple liver lesions   
after a latency of 3–4 mo and had to be euthanized within   
5–8 mo because of tumor burden (Fig. 1 A); these mice did not 
develop any other visible pathology outside the liver (not 
depicted).  Quantitative  RT-PCR  (RT-qPCR)  analysis  with 
RNA  extracted  from  macro-dissected  tumors  showed  de-
creased expression of Rb and p130, confirming deletion of these 
two genes (Fig. 1 B). The presence of one p130 or p107 allele 
was sufficient to prevent the development of liver tumors at the 
same time points (Fig. S1 B and not depicted). Cells in these le-
sions were actively cycling, as visualized by immunostaining for 
BrdU incorporation (Fig. 1 C) and by immunoblot analysis for 
known markers of proliferation (Fig. S1 C). Finally, TKO liver 
tumors could be serially transplanted in immunocompromised 
mice, confirming their tumorigenic potential (Fig. S1, D–F).
TKO  tumors  expressed  high  levels  of  Afp,  a  molecular 
marker of HCC (Fig. 1 D), and were classified histopathologi-
cally as trabecular lesions with features of hepatocytes (Fig. 1, E 
and  F).  Immunostaining  experiments  further  indicated  that 
TKO tumors were composed of cells expressing heterogeneous 
levels of Albumin (a hepatocyte marker) but undetectable levels 
of CK19 or EpCAM (cholangiocyte markers; Fig. 1 G and 
Fig. S1 G), similar to most human HCCs. To further assess the 
relevance of the TKO model to human HCC, we performed a 
microarray analysis comparing TKO tumors to human HCCs. 
A previous analysis of gene expression profiles from a large set 
of human HCCs identified six HCC subgroups (G1–G6), each 
with different molecular features (Boyault et al., 2007). We 
found that TKO tumors clustered preferentially with the G1–
G3 groups (Fig. 1 F). Interestingly, some TKO tumors clustered 
with human G3 tumors, which are characterized in part by the 
expression of several genes implicated in cell cycle control, in-
cluding E2F target genes, and by the methylation of the 
CDKN2A locus, which codes for p16INK4a, an upstream regu-
lator of the entire RB family. Together, these observations indi-
cate that the tumors growing in the liver of TKO mice provide 
a novel model for human HCC.
Expansion of the stem/progenitor compartment upon 
deletion of Rb family genes in the liver of adult mice
The early stages of cancer initiation are challenging to study 
in HCC patients, who are often diagnosed with advanced 
disease, but are readily accessible to in vivo analysis in mouse 
itself are rare, but the RB protein is often undetected in 
HCC cells (Edamoto et al., 2003; Laurent-Puig and Zucman-
Rossi, 2006; Knudsen and Knudsen, 2008). Furthermore, 
Gankyrin, an E3 ligase that triggers degradation of RB 
family members, is overexpressed in the majority of HCC 
tumors (Higashitsuji et al., 2000). Finally, the RB pathway 
is also inactivated in liver cells by viral proteins: for exam-
ple, hepatitis B virus infection results in the constitutive 
expression of viral proteins such as preS2 and HBx, which 
directly  or  indirectly  activate  Cyclin–CDK  complexes 
(Park et al., 2006; Hsieh et al., 2007; Wang et al., 2008; Kim 
et al., 2010b). Similarly, recruitment of the E6AP ubiquitin 
ligase by the hepatitis C virus protein NS5B leads to the 
degradation of RB and potentially p107 and p130 (Munakata 
et al., 2007). These observations suggest a yet untested model 
in which overall inactivation of the RB pathway by simul-
taneous decreased function of the three RB family mem-
bers may be necessary for HCC development. This idea is 
supported by the observation that deletion of the Rb (Rb1) 
gene in the mouse liver is not sufficient to drive HCC devel-
opment (Williams et al., 1994; Mayhew et al., 2005).
Many of the events resulting in the functional inactiva-
tion of the RB pathway in human HCC occur early in the 
course of the disease, suggesting that the RB pathway may 
play an important role in the prevention of HCC initiation 
(Zhang et al., 2006; Nordenstedt et al., 2010). However, 
identifying the cell type or types from which HCC may 
originate is not currently possible in patients. Mature hep-
atocytes (parenchymal cells) in the liver have the capacity 
to proliferate and could therefore serve as the cell of origin 
for HCC (Oertel and Shafritz, 2008; Duncan et al., 2009; 
Benhamouche et al., 2010). In addition, the portal triad, a 
structure composed of a bile duct, a portal vein, and a he-
patic artery, is thought to serve as a niche for several popu-
lations of stem and progenitor cells (nonparenchymal cells; 
Susick et al., 2001; Schmelzer et al., 2006; Zhang et al., 
2008). These progenitor cells, often termed oval cells, also 
have the capacity to expand in response to stress and injury 
(Erker and Grompe, 2008; Duncan et al., 2009). All of these 
different liver cell populations may serve as a cell of origin 
for HCC. Unfortunately, the current lack of a comprehen-
sive knowledge of the different stages of differentiation in 
the hepatocytic lineage has hampered a thorough investi-
gation of the cellular origin of HCC (Lee and Thorgeirsson, 
2006; Zhang et al., 2008; Duncan et al., 2009; Mishra et al., 
2009; Dorrell et al., 2011; Shin et al., 2011).
In this study, we sought to address the molecular and cel-
lular mechanisms of HCC development upon loss of RB 
pathway function. We show that Rb family triple KO (TKO) 
mice, in which the RB pathway is genetically inactivated, de-
velop liver cancer with histological and molecular similarities 
to human HCC. In addition, we show that loss of RB family 
function allows the expansion of normally quiescent popula-
tions of stem/progenitor cells, and we identify activation of 
Notch signaling as a suppressor feedback mechanism during 
HCC progression.JEM Vol. 208, No. 10 
Article
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strikingly, very little proliferation was observed in popula-
tions of mature hepatocytes surrounding the early lesions 
(Fig. 2 C; see a second example in Fig. S2, C and E). Little, 
if any apoptotic cell death was observed by immunostaining 
for cleaved caspase 3 on sections from control and TKO 
mice at these early time points (not depicted). This analysis 
suggested that loss of RB family members in the liver of 
adult mice leads rapidly and specifically to the proliferation 
of  progenitor-like  cells  (Roskams  et  al.,  2003;  Dorrell   
et al., 2008).
Evidence suggests that CK19 and EpCAM, which are 
markers of normal cholangiocytes, may also be expressed in 
certain populations of liver progenitor cells (Libbrecht, 2006; 
Schmelzer et al., 2006;  Yovchev et al., 2008; Zhang et al., 2008; 
Duncan et al., 2009). However, we did not detect expression 
of these markers by immunostaining in the small lesions 
growing in the liver of TKO mice. The A6 antigen is also a 
marker of both liver progenitor cells and 
bile  duct  cells  (Engelhardt  et  al.,  1993; 
Haybaeck et al., 2009), and we found an 
expansion of A6+ cells around the portal 
triad of cTKO mice 2–3 wk after Cre 
induction (Fig. S2, F–K). Several cells in 
the TKO  lesions  were  also  positive  for 
Sox9, a recently identified marker of liver 
progenitors (Fig. S2, L–N; Dorrell et al., 
2011). Similarly, we used antibodies against 
models. We examined tumor development 1–5 wk after Cre-
mediated inactivation of Rb family genes in the liver of adult 
cTKO mice. At these time points, the mutant liver appeared 
macroscopically normal (not depicted), but liver sections 
showed the progressive appearance of foci of small cells growing 
next to the portal triad; these cells had a high nuclear/ 
cytoplasm ratio and often displayed an oval shape as well as 
some histopathological features of hepatocytes (Fig. 2 A 
and Fig. S2 A).  Immunostaining for  glutamine  synthase 
(GS), a marker of centrilobular hepatocytes (Gebhardt and   
Hovhannisyan, 2010), confirmed that the small lesions were 
growing next to portal triads, away from central veins (Fig. 2 B). 
The adult liver is a quiescent organ, and very few cells stained 
positive for the cell cycle marker Ki67 on liver sections from 
control mice 2–4 wk after Ad-Cre infection (not depicted). In 
contrast, immunostaining for Ki67 on liver sections from TKO 
mice showed that cells in the small lesions were proliferative; 
Figure 1.  Genetic inactivation of the Rb gene 
family in the mouse liver results in HCC devel-
opment. (A) One representative (n > 20) TKO 
mouse with tumors (asterisks) in the liver is shown 
4 mo after intrasplenic Ad-Cre injection. All experi-
ments were performed on TKO mice 3–4 mo after 
Ad-Cre injection. (B) RT-qPCR analysis of Rb and 
p130 messenger RNA (mRNA) expression in TKO 
tumors (n = 9) and control livers (n = 5; CTRL,  
Rblox/lox;p130lox/lox;p107/). (C) Immunostaining on 
TKO liver sections for the DNA replication marker 
BrdU. Areas of proliferation are circled with dashed 
lines. (D) RT-qPCR analysis of Afp mRNA levels in 
TKO tumors (n = 9) and CTRL livers (n = 5). (E) H&E 
staining of TKO liver sections with multiple inde-
pendent tumors (delineated by dashed lines). (F) At 
higher magnification, tumor cells resemble small 
hepatocytes. (G) Representative sections (n > 20) 
from CTRL and TKO livers were stained with DAPI, 
CK19, and Albumin (Alb). The white arrows point  
to a bile duct. Merged pictures are shown on the 
right. (H) Nonsupervised hierarchical clustering of 
gene expression profiles from human HCCs and 
mouse TKO tumors (blue asterisks). The black bar 
marks human tumors in the group G3, which  
are characterized in part by methylation of  
the CDKN2A locus. The green bar marks normal 
human liver samples, and the red bar marks CTRL 
mouse livers. Error bars indicate SEM. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001. Bars: (C, E, and G)  
50 µm; (F) 5 µm.1966 Notch activation slows HCC progression | Viatour et al.
In this model, the CreER fusion protein is broadly 
expressed and can be activated upon Tam injection to 
inactivate  the  RB  family  in  multiple  tissues  and   
organs (Viatour et al., 2008; Burkhart et al., 2010). 
We found that induction of Cre activity by Tam in 
this system was often more efficient than with 
Ad-Cre, as judged by the analysis of a  YFP reporter 
(Fig. S2, T–W); we also found an expansion of cells 
with progenitor cell markers in Rosa26CreER TKO 
mice (Fig. S2 B and not depicted). In this Rosa26CreER 
cTKO system as with Ad-Cre cTKO mice, we did 
not observe any increase in liver size at preneoplastic 
stages (not depicted).
Rosa26CreER TKO and Ad-Cre TKO mice were used inter-
changeably to measure the expression of the Sca1, C3, C7, 
and E10 surface markers by flow cytometry. These experi-
ments confirmed that both Sca1+ cells and C3/C7/E10+ cells 
(where the three antibodies were pooled in the FACS analysis) 
increased in frequency in TKO livers shortly after Cre activa-
tion (Fig. 3, A and B). Interestingly, only a minor fraction of 
cells were double positive for Sca1 and C3/C7/E10 (Fig. 3 A), 
indicating that these antigens marked distinct populations of 
cells. Because the expansion of progenitor cells in TKO mice 
could be caused by a non–cell autonomous, reactive activa-
tion of these cells, we measured p130 levels in Sca1+ and/or 
C3/C7/E10+ cells isolated from TKO mice compared with 
control mice. We found decreased levels of p130, suggesting 
that the expanding progenitor cells were indeed mutant for 
the Rb family (Fig. 3 C). These data confirmed the observa-
tion made with the inducible GFP reporter that Cre had been 
activated in cells within early lesions (Fig. 2 C). We next sought 
to gain more insights into the biology of the TKO progenitor 
cells by examining some characteristics of stem/progenitor 
cells in these populations. Compared with C3/C7/E10+ cells, 
we found that Sca1+ cells were cycling more slowly (Fig. 3 D 
and Fig. S3, A and B), had higher expression levels of the stem 
cell marker Bmi1 (Fig. 3 E; Valk-Lingbeek et al., 2004), and 
Sca1, a marker expressed at the surface of mouse stem/ 
progenitor cells in different tissues (Holmes and Stanford, 
2007), including in the liver (Clayton and Forbes, 2009), and 
found an expansion of Sca1+ cells within the small lesions by 
immunostaining (Fig. 2 D). A panel of antibodies that recog-
nize specific surface epitopes on cells activated during an oval 
cell response initiated by DDC (3,5-diethoxycarbonyl-1,4-
dihydrocollidine) treatment was recently developed (Dorrell 
et al., 2008). Among the nine monoclonal antibodies that we 
tested, only MIC1-1C3 (C3), OC2-3C7 (C7), and OC2-
6E10 (E10) consistently stained TKO early lesions, albeit with 
variable frequency and intensity (Fig. 2 E and Fig. S2, O–Q). 
The  difference  in  signal  intensity  suggests  that  progenitor 
cells expanding in the DDC and TKO models are only par-
tially overlapping, which is supported by the different histo-
logical structures developed in the two models (Fig. S2, R and S). 
Thus, cells expanding in the liver of TKO mice express 
markers that are characteristic of subpopulations of adult liver 
stem/progenitor cells, providing additional support to a model 
in which loss of RB family function leads to the expansion of 
populations of liver progenitor cells.
To control for reactive effects to the adenoviral infection 
in the liver, we used intraperitoneal injection of tamoxifen 
(Tam) in Rosa26CreER cTKO mice to delete Rb and p130.   
Figure 2.  Inactivation of the Rb gene family in the 
adult liver results in the expansion of cells with fea-
tures of stem/progenitor cells. (A) Representative H&E 
staining (n > 20) of the liver of a cTKO mouse infected with 
Ad-Cre (4 wk after the injection) shows that TKO early liver 
lesions are composed of small cells. White dashed lines indi-
cate lesions. All mice used were between 2 and 4 mo of age 
at the time of injection. PT, portal triad. (B) Sections from 
TKO liver were stained antibodies against GS (green),  
a marker of hepatocytes around the central vein (CV). Immuno-
fluorescence images were merged with DAPI (blue)  
images. The white arrows indicate early TKO lesions. (C) Early 
lesions in cTKO;Rosa26LSL-YFP mice infected with Ad-Cre were 
immunostained for Ki67 and GFP. White dashed lines indi-
cate lesions. (D) Control (CTRL) and TKO liver sections were 
stained with Sca1 antibodies. The white arrows point to 
Sca1-positive cells. (E) CTRL and TKO livers were stained with 
C3, C7, and E10 antibodies. Immunofluorescence images 
were merged with DAPI images. White arrows indicate early 
lesions. Bars: (A–D and E, top) 5 µm; (E, bottom) 50 µm.JEM Vol. 208, No. 10 
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smaller  colonies 
(Fig. 3, H and I), 
which  could  be 
related  to  their 
slower cell cycle (Fig. 3 D). Together, these data show that in-
activation of the RB pathway in the liver of adult mice specifi-
cally leads to the expansion of populations of stem/progenitor 
cells, suggesting that these cells initiate HCC development.
Up-regulation of E2F and Myc activities in TKO HCC cells
To understand the molecular changes that occur during the 
development of HCC in TKO mice, we first ran the SAM 
(significance analysis of microarrays) statistical method to 
compare the TKO dataset with a control liver dataset. The 
three most induced genes in TKO tumors, H19, Tff3, and 
Rrm2, are molecular markers of human HCC (Sohda et al., 
1998; Okada et al., 2005; Satow et al., 2010). This analysis also 
showed increased expression of genes involved in the regu-
lation of cell cycle, DNA synthesis, and DNA repair in the TKO 
dataset, including known E2F target genes (see Table S1 for 
selected  genes  and Table  S2  for  the  entire  list).  DAVID   
(Database for Annotation, Visualization, and Integrated Dis-
covery) analysis indicated that many of the genes up-regulated in 
the TKO dataset have a known role in cell cycle progression, 
DNA  repair,  and  chromosome  maintenance  (Table  S1). 
expressed lower levels of the Ck19 and Albumin differentia-
tion markers (Fig. 3 F).
One common characteristic of stem/progenitor cells is 
their ability to form colonies in defined culture conditions. 
When  placed  in  culture, TKO  nonparenchymal  cells  pro-
duced more colonies than nonparenchymal cells from control 
mice (Fig. 3 G). Under these conditions, although control 
cells absolutely required epidermal growth factor (EGF) and 
hepatocyte growth factor (HGF) to form colonies, cells from 
TKO livers formed colonies in the absence of these growth 
factors, although not to the extent of cells with EGF and 
HGF. Nonparenchymal TKO cells were able to form lesions 
resembling the lesions growing in the liver of TKO mice 
when transplanted into the liver of immunodeficient mice 
(Fig. S3 C), but they failed to form tumors when transplanted 
under the skin (not depicted). This observation and the partial 
growth factor independence suggest that, at this early stage, 
TKO liver cells in the small lesions still require an appropriate 
microenvironment to expand. When we used flow cytometry 
to further identify the cells in the liver of TKO mice that had 
the ability to form colonies in culture, we found that Sca1/
C3/C7/E10 cells from TKO mice reproducibly failed to 
produce colonies under these conditions (unpublished data). 
In  contrast,  both  Sca1+  and/or  C3/C7/E10+ TKO  cells 
formed  colonies,  although  Sca1+  cells  formed  fewer  and 
Figure 3.  HCC development is associated 
with an expansion of the progenitor com-
partment in TKO mice. (A) Representative FACS 
analysis (n = 4) of nonparenchymal cells 2 wk 
after Cre-mediated recombination in TKO mice 
compared with controls (CTRL). The nonhemato-
poietic fraction (CD45low) was analyzed for Sca1 
and C3/C7/E10 expression. (B) Numbers of Sca1+ 
and C3/C7/E10+ cells in the nonparenchymal frac-
tions of TKO livers (n = 4 for each genotype).  
(C) The expression of p130 was assessed by  
RT-qPCR in Sca1+ and C3/C7/E10+ subsets of control 
and TKO nonparenchymal cells (n = 3). (D) Cell 
cycle activity in TKO C3/C7/E10+ cells compared 
with TKO Sca1+ cells was measured by propidium 
iodide staining of fixed cells isolated by FACS  
(n = 4). (E) Expression of Bmi1 in Sca1+ and C3/C7/
E10+ populations from control and TKO mice in 
early lesions, as assessed by RT-qPCR (n = 3).  
(F) Expression of Albumin and CK19 in C3/C7/E10+ 
or Sca1+ TKO cells (n = 3). (G) Colony-forming 
activity of unfractioned nonparenchymal cells 
from either control or TKO mice. Colonies were 
either grown in the presence or absence of EGF 
and HGF. Plates were stained with crystal violet 
after 8 d before counting (mean of four indepen-
dent experiments). (H and I) Colony-forming  
activity of control and TKO Sca1+ and C3/C7/E10+ 
populations. Colony assay was performed in  
24-well plates with sorted CTRL and TKO cells 2 wk 
after Cre-mediated recombination. (H) Represen-
tative pictures of colonies formed by C3/C7/E10+ 
(top) and Sca1+ (bottom) TKO cells. (I) Quantifica-
tion of H. Colonies were fixed and stained after  
8 d before counting (mean of three independent 
experiments). Error bars indicate SEM. *, P < 0.05; 
**, P < 0.01; ns, not significant.1968 Notch activation slows HCC progression | Viatour et al.
Transcriptional up-regulation of the Notch signaling 
pathway in TKO HCC cells
GSEA also identified enrichment for signaling pathways other 
than E2F and Myc in TKO HCCs compared with control 
livers (Fig. 4 D), including pathways such as the Wnt, p38 
MAPK (mitogen-activated protein kinase), and Ras pathways, 
which are known to be involved in human HCC develop-
ment  (Laurent-Puig  and  Zucman-Rossi,  2006; Villanueva   
et al., 2007; Whittaker et al., 2010; Min et al., 2011) and could 
cooperate with E2F and c-Myc activities in the development 
of TKO tumors. Potential changes in the Notch signaling 
pathway were also detected by GSEA. Although Notch sig-
naling has been shown to play a critical role in cell fate deci-
sions during liver development, little is known regarding its 
possible role in liver cancer development (Li et al., 1997; Qi 
et al., 2003; Geisler et al., 2008; Zong et al., 2009; Hofmann 
et al., 2010). Changes in the expression of genes in the Notch 
pathway in TKO HCCs were supported by the presence of 
Notch pathway members in a cluster of genes that are specifi-
cally up-regulated in the TKO HCC model compared with 
other HCC mouse models; this cluster includes Notch recep-
tors (Notch1–4), as well as a downstream transcriptional target 
of the Notch pathway (Nrarp; Fig. 4, A and E; and 
supplemental text; Pirot et al., 2004). RT-qPCR 
analysis  confirmed  that  Notch1  and  Nrarp  were 
specifically up-regulated in TKO tumors compared 
with c-Myc–induced HCC (Fig. 4 F), suggesting 
that this up-regulation was specific to tumors with 
inactivation of the RB pathway.
RT-qPCR analysis further showed that the   
expression of several components of the Notch   
Nonsupervised  hierarchical  clustering  showed  that TKO 
HCC tumors clustered closely with mouse liver tumors ini-
tiated by the overexpression of E2F1 and c-Myc (Fig. 4 A; 
Conner et al., 2000; Lee et al., 2004). Accordingly, c-Myc 
levels were higher in TKO liver tumors than in control livers 
(Fig.  4  B),  and  a  gene  set  enrichment  analysis  (GSEA) 
showed significant enrichment in the TKO dataset for genes 
in  a  Myc-centered  regulatory  network  independent  of  a 
core embryonic stem cell program (Fig. 4 C and not de-
picted; false discovery rate [FDR] q-value 0.045; Kim et al., 
2010a). GSEA with the TKO dataset and a library of curated 
gene  sets  (see  Materials  and  methods  and Table  S3)  also 
showed significant enrichments for c-Myc, E2F1, and E2F3 
(Fig. 4 D and supplemental text). Together, the observa-
tions  that  E2F  and  Myc  activities  are  elevated  in TKO   
tumors, previous findings that ectopic expression of either 
E2F1 or c-Myc is sufficient to initiate HCC (Conner et al., 
2000; Lee et al., 2004), and the rapid appearance of multiple 
lesions in the liver of TKO mice suggest that loss of RB 
family function is sufficient to initiate HCC development   
in the liver of mice by promoting the proliferation of the 
mutant cells.
Figure 4.  Activation of cellular signaling pathways in 
TKO HCC cells. (A) Nonsupervised hierarchical clustering of 
datasets from various mouse HCC models (TKO, c-Myc over-
expression, and E2F1 overexpression). Datasets from differ-
ent platforms were first normalized before analysis (see 
Materials and methods). A cluster of genes specifically up-
regulated in the TKO dataset was identified (cluster M; sup-
plemental text). The color scale is drawn relative to each 
gene (each row) with blue representing the lowest expres-
sion and red the highest. (B) RT-qPCR of c-Myc expression in 
five control livers (CTRL) and nine TKO HCC samples. (C) GSEA 
shows a significant enrichment in the TKO dataset of a pre-
defined gene list that is specific for a core Myc signature 
(Myc module). (D) GSEA analysis was performed by compar-
ing the TKO dataset (Table S2) with the entire list of curated 
gene sets available. The entire list of gene sets enriched in 
the TKO dataset is displayed in Table S3. The gene sets (path-
ways) are ranked from the highest to the lowest score (NES: 
most significant, left). Significant p-value is <0.05, and sig-
nificant FDR is <0.25. (E) The genes in cluster M were pro-
cessed through DAVID analysis for GO annotations, and the 
top enrichment scores and p-values are shown. (F) RT-qPCR 
analysis of Notch1 and the Notch pathway target Nrarp in 
TKO HCCs compared with c-Myc–induced HCCs and control 
liver samples (n = 3). Error bars indicate SEM. *, P < 0.05;  
**, P < 0.01.JEM Vol. 208, No. 10 
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pathway members responded to RB reintroduction under 
these specific conditions (Fig. 5 F). Together, these experiments 
indicate a direct control of the Notch signaling pathway in 
HCC cells by the RB/E2F axis, providing one explanation 
why loss of Rb family genes results in the enhanced transcrip-
tion of Notch pathway genes in these tumor cells.
Notch signaling inhibits the expansion of HCC cells
Potentially as a result of this transcriptional activation by 
E2F, Notch signaling was activated in TKO HCC, as illus-
trated by the increased level of the cleaved active form of 
the Notch1 (intracellular domain [ICD] of Notch [NICD]) 
protein compared with control liver cells (Fig. 6 A) and the 
induction of the Notch target Nrarp in TKO tumor cells 
(Fig. 4 F). Furthermore, immunostaining on tumor sec-
tions revealed that the Notch target HES1 and Notch1 itself 
(but not Notch2) were expressed in the nucleus of TKO 
HCC cells in vivo, which is a sign of Notch pathway acti-
vation (Fig. S4).
To determine the functional role of the Notch pathway in 
TKO mice, we treated TKO mice 75 d after Ad-Cre injec-
tion, at a time when small tumors were present, with DAPT, 
a -secretase inhibitor which blocks the Notch pathway by 
preventing the cleavage of the internal domain of the Notch 
receptor (Hellström et al., 2007). 12 d after the beginning of 
treatment, we found 
that  the  liver  from 
pathway, including Notch1, Notch3, and Notch4, as well as two 
other canonical Notch target genes, Hes1 and Hey1, was sig-
nificantly increased in TKO HCC cells compared with con-
trol liver cells (Fig. 5 A). This increase in the transcription of 
several genes in the Notch pathway in Rb family mutant cells 
raised the possibility that it was a direct consequence of 
the activation of E2F transcription factors. Indeed, reporter 
gene assays showed that promoters of the mouse Hes1 gene 
and the human NOTCH1 gene could be activated by E2F1 
and E2F3, two transactivating members of the E2F family 
(Fig. 5 B). Chromatin immunoprecipitation (ChIP) assays 
showed direct binding of E2F1 and E2F3 to the proximal 
promoter regions of Dtx3, Dtx4, Notch1, Notch3, Hes1, and 
Hey1 in a cell line derived from a TKO HCC (Fig. 5 C and 
not depicted). E2F binding to the promoter region of Notch 
pathway genes was also observed in WT mouse adult livers;   
in particular, we found increased binding of E2F4, a repressor 
E2F, to several of the promoters tested in these quiescent liver 
cells (Fig. 5 D), correlating with the lower transcription of 
Notch pathway genes in normal liver (Fig. 5 A). To determine 
whether this finding was specific to mouse cells, we per-
formed similar experiments with the human HCC cell lines 
Hep3B and SNU-449 and found binding of E2F1, E2F3, and 
E2F4 to the same Notch pathway gene promoters (Fig. 5 E 
and not depicted). Reintroduction of RB in mouse HCC 
cells led to the repression of the E2F target gene Ccna2 as well 
as the Notch pathway member Hey1, although not all Notch  Figure 5.  Notch signaling is regulated in 
HCC cells by E2F transcription factors.  
(A) RT-qPCR analysis was performed on five 
control livers (CTRL) and nine TKO HCC sam-
ples to detect the expression of members of 
the Notch pathway. (B) Reporter gene assays 
to measure the transactivation of the murine 
Hes1 promoter (left; light gray) and the  
human NOTCH1 promoter (right; gray) by 0.2 
and 1 µg E2F1 or 1 µg E2F3. Data are repre-
sentative of three independent experiments 
performed in Saos cells. (C–E) ChIP analysis 
for E2F1, E2F3 (activating E2Fs), and E2F4 
(repressor E2F) binding to the promoter of 
members of the Notch pathway in a cell line 
derived from a TKO HCC (C), WT primary 
mouse liver cells (D), and a human HCC cell 
line, Hep3B (E). A p16 antibody was used as a 
negative control. Binding to the Cyclin A 
(Ccna2) promoter, a well-known E2F target, 
was used as a positive control. Displayed  
images are representative of three indepen-
dent experiments. (F) Reintroduction of RB in 
mouse HCC cells. Two cell lines derived from 
TKO HCCs were transfected with a plasmid 
expressing GFP (empty vector) or a fusion 
protein composed of GFP and the large pocket 
domain of RB (RB reintroduction). GFP- 
positive cells were isolated by FACS 40 h after 
transfection, and the expression of Ccna2, 
Hey1, and Hes1 was assessed by RT-qPCR  
(n = 3). Error bars indicate SEM. *, P < 0.05;  
**, P < 0.01; ***, P < 0.001; ns, not significant.1970 Notch activation slows HCC progression | Viatour et al.
human HCC (C3a, SNU-449, and HepG2). We found that 
expression of Notch1 ICD was sufficient to inhibit the pro-
liferation of three out of the four cell lines tested (TKO1, 
TKO2, and SNU-449 but not HepG2; Fig. 6 G and not de-
picted) and also induced an apoptotic response in four out of 
the five cell lines tested (TKO1, C3a, HepG2, and SNU-449 
but not TKO2; Fig. 6 H). These findings indicate that activa-
tion of the Notch signaling pathway after activation of E2F in 
RB family mutant HCC cells serves as a negative feedback 
mechanism to slow the expansion of the tumor cells.
Activation of Notch signaling is critical for biliary differentia-
tion of liver progenitors (Li et al., 1997; Geisler et al., 2008; 
mice treated with DAPT exhibited macroscopically visible 
tumors that were not present in vehicle-treated mice (not de-
picted). Sections from vehicle-treated and DAPT-treated mice 
showed a significant increase in tumor area and tumor num-
bers (Fig. 6, B–E). Nrarp expression was decreased in DAPT-
treated  tumors  compared  with  vehicle-treated  tumors, 
indicating that DAPT treatment did inhibit Notch signaling, 
as expected (Fig. 6 F). To directly test whether activation of 
Notch signaling was sufficient to block the proliferation of 
HCC cells in a cell intrinsic manner, we overexpressed the 
constitutively active ICD of Notch1 in liver tumor cell lines 
derived either from TKO mice (TKO1 and TKO2) or from 
Figure 6.  The Notch signaling pathway 
inhibits the expansion of HCC cells.  
(A) Immunoblotting analysis of activated 
Notch1 (Notch1ICD) in three control livers 
(CTRL) and eight independent TKO tumors. 
GAPDH serves as a loading control. (B) H&E 
staining of liver sections from TKO mice 
treated with DAPT (n = 4) or vehicle control  
(n = 4). Bar, 50 µm. (C) Quantification of tumor 
area compared with the total area in DAPT- 
and vehicle-treated (Veh) TKO mice (n = 4).  
(D) Quantification of tumor numbers by sur-
face area (n = 4). (E) Quantification of small 
and large tumors. The cutoff was arbitrarily 
set at 10,000 µm2, which corresponds to the 
size of early TKO lesions (n = 4). (F) Analysis of 
Nrarp mRNA levels in tumors upon DAPT 
treatment by RT-qPCR (n = 4). (G) Four HCC 
cell lines (two TKO cell lines, human cells 
SNU-449 and HepG2) were infected with 
MigR1-IRES-GFP retroviruses either empty 
(CTRL) or expressing NICD, and GFPhigh cells 
were isolated by FACS. (left) GFP expression in 
control and NICD-expressing cells. (right) 
Sorted cells were analyzed for propidium 
iodide incorporation and growth in culture. 
The number of cells was quantified 90 h after 
plating 20,000 cells. Data are representative 
of two independent experiments. (H) Five HCC 
cell lines (TKO1, TKO2, C3a, HepG2, and SNU-
449) were infected with MigR1-IRES-GFP 
either empty (CTRL) or expressing NICD. GFPhigh 
cells were isolated by FACS and allowed to 
rest in culture for 72 h, after which survival 
was measured by Annexin V staining. Data are 
representative of two independent experi-
ments. (I) C3/C7/E10+ nonparenchymal cells 
were FACS sorted, and 5,000 cells were plated 
in culture. Cells were infected with MigR1-
IRES-GFP either empty (CTRL) or expressing 
NICD and counted 7 d after infection (n = 4). 
(J) The TKO dataset clusters with the subgroup 
B of human HCC after nonsupervised hierar-
chical clustering analysis of 3,497 mouse and human orthologues. (K) Nonsupervised hierarchical clustering of a curated gene set representing the Notch 
pathway (17 genes, including ligands, receptors, and target genes). Expression of Notch pathway genes was retrieved from a dataset of 53 primary human 
HCCs with good (group B) and bad (group A) prognosis. (L) A curated set of 17 genes in the Notch pathway (same as in K) predicts survival in HCC  
patients (OS, overall survival in months over a 5-yr period). Error bars indicate SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.JEM Vol. 208, No. 10 
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DISCUSSION
In this study, we describe the consequences of genetically 
inactivating the Rb gene family in the liver of adult mice. 
We found that Rb family TKO mice develop HCC, pro-
viding a novel tractable mouse model for this deadly human 
cancer. Using this genetically defined model, we identified 
adult progenitor cells as initiating populations in HCC devel-
opment upon inactivation of the RB pathway and we uncov-
ered a potential tumor suppressor role for Notch signaling in 
human HCC.
RB family members display extensive functional overlap 
in many cell types, including in liver cells (Reed et al., 2009). 
In fact, we found that the presence of one WT allele of p107 
or p130 was sufficient to prevent HCC development for at 
least 6–8 mo after Cre activation, similar to our observation in 
the hematopoietic compartment, indicating that reintroduc-
tion of one Rb family allele significantly impairs tumor develop-
ment (Viatour et al., 2008). We cannot exclude the possibility 
that these mice will eventually develop HCC at later time 
points; indeed two of the cell lines that we have isolated thus 
far from TKO mice have retained a WT p130 allele (un-
published data). Although it is difficult to directly compare 
the genetic deletion of Rb family genes in the mouse sys-
tem to the protein inactivation by degradation or phosphory-
lation observed in human HCC, these results support the 
observation that most events targeting the RB pathway in 
HCC simultaneously inactivate the three RB family proteins 
(see introduction).
An important question in the liver cancer field is whether 
HCC initiates from hepatocytes and/or earlier progenitors in 
the adult liver, a question which is challenging to address in 
patients. Cre activation in cTKO mice results in the prolifera-
tion and rapid expansion of cells with characteristics of liver 
stem/progenitor  cells,  including  their  morphology,  their   
localization close to the portal triad, and their expression of   
specific markers. At the same time point, we observed only 
limited DNA replication in mature hepatocytes and no evi-
dence of clonal expansion. These observations, together with 
the fact that a fraction enriched for nonparenchymal progeni-
tor cells can recapitulate tumor development upon transplan-
tation, strongly suggest that TKO HCC tumors initiate from 
the stem/progenitor compartment in the liver of mice. The 
stem/progenitor cell hypothesis is supported by evidence that 
Cullin 3, a regulator of Cyclin E (an inhibitor of the RB family), 
prevents liver cancer development from liver progenitors 
(Kossatz et al., 2010).
Although  EpCAM  and  CK19  have  been  proposed  to 
mark some liver progenitors (Schmelzer et al., 2006; Zhang 
et al., 2008), immunostaining and FACS analysis (unpublished 
data) for these markers did not identify EpCAM+ or CK19+ 
cells in TKO early lesions. One interpretation of this observa-
tion is that TKO lesions initiate from progenitors that are dis-
tinct from EpCAM+ or CK19+ progenitors, which would 
underscore the heterogeneity of liver stem/progenitor cell 
populations. This idea is supported by the observation that 
progenitor cells expanding upon inactivation of the NF2 
Hofmann et al., 2010; Roskams et al., 2010; Onoyama et al., 
2011). This observation raised the question of the status of 
Notch  signaling  in  the  liver  progenitor  populations  from 
which TKO HCCs may arise. RT-qPCR analysis from FACS-
sorted Sca1+ and C3/C7/E10+ liver progenitor cells and hep-
atocytes showed that Notch1 signaling was significantly 
higher in progenitor cell populations compared with mature 
liver cells (Fig. S5 A). Immunostaining for HES1 and nuclear 
Notch1 confirmed the activation of the Notch pathway in 
early TKO lesions (Fig. S4). However, although the Notch 
pathway  is  transcriptionally  activated  in TKO  hepatocytes 
compared with their controls, loss of the three RB family pro-
teins did not further induce the expression of Notch1, Hes1, 
Hey1, or Nrarp in TKO progenitors (Fig. S5 A). These findings 
suggest that transcriptional control of Notch pathway genes by 
RB family members is cell type dependent and evolves during 
tumor  progression,  being  more  apparent  in  cells  with  low 
Notch pathway activity. We found no differences in TKO pro-
genitor cell numbers or in their cell cycle activity upon treat-
ment with DAPT in vivo (Fig. S5, B–D), possibly because high 
Notch activity in these cells renders them less sensitive to par-
tial inhibition of the Notch pathway by DAPT. However, the 
colony-forming activity of TKO liver progenitor cells in cul-
ture was significantly impaired when these cells were sorted 
from mice and infected with a Notch1 ICD retrovirus (Fig. 6 I), 
similar to what we had observed with HCC cells (Fig. 6 G). 
This observation suggests that hyperactivation of Notch sig-
naling also inhibits the proliferation of liver progenitor cells.
To address the relevance of the findings that activation of 
Notch signaling may serve as a mechanism to dampen the 
proliferation of HCC cells to HCC patients, we took advan-
tage of a dataset in which gene expression profiles are linked 
to patient survival (Lee et al., 2004). In this study, clustering 
analysis had led to the identification of two major HCC mo-
lecular groups, with group B patients showing a better sur-
vival than group A patients. We found that the TKO dataset 
preferentially clustered with human tumors of the B subgroup 
(Fig. 6 J), similar to what had been previously observed for   
tumors expressing Myc and E2F1 (Lee et al., 2004). Interest-
ingly, the expression level of the human NOTCH1 and HES1 
genes was significantly higher in group B versus group A (P < 
0.05). However, removal of these Notch pathway genes from 
the analysis did not change the clustering of TKO tumors to 
group B (unpublished data), indicating that other genes or 
pathways may be involved in the enhanced survival of patients 
in group B. The analysis of recent genome-wide ChIP experi-
ments indicates that RB may directly bind to the promoters 
of  other  genes  in  the  Notch  pathway  such  as  JAG1  and 
PSEN2 in senescent fibroblasts (Chicas et al., 2010; unpub-
lished data). These observations and our data in HCC cells led 
us to test the role of a broader Notch pathway signature in 
HCC. We found that a curated list of 17 genes used as a signa-
ture of the Notch pathway independently predicted increased 
survival in HCC patients (Fig. 6, J and K; and Fig. S5 E). 
Therefore, activation of Notch signaling in HCC may act as a 
mechanism to limit the expansion of HCC cells in patients.1972 Notch activation slows HCC progression | Viatour et al.
genes in TKO liver progenitor cells suggests that this link is 
context dependent. More work is needed to understand the 
regulation of Notch pathway genes by E2F family members 
in different cell types. Functionally, our data showing that in-
creased Notch activity leads to cell cycle arrest in G2 and/or 
cell death might be related to observations that inactivation   
of Rb family genes induces a G2 arrest in TKO fibroblasts 
(van Harn et al., 2010).
In  vivo  modulation  of  Notch  pathway  activity  with 
DAPT, a -secretase inhibitor and potent inhibitor of Notch 
signaling, resulted in accelerated cancer development in TKO 
mice. Interestingly, liver-specific inactivation of Notch1 ex-
pression, although not sufficient to promote HCC, leads to 
the proliferation of hepatocytes in mice (Croquelois et al., 
2005). In contrast, in vivo DAPT treatment failed to increase 
proliferation in TKO progenitor cells, either because these 
cells have already reached a very high level of cell cycle activ-
ity or because DAPT treatment is not sufficient to block 
Notch signaling in progenitor cells. In vitro, we found that 
activation of Notch signaling in mouse and human HCC 
cells was sufficient to block their expansion, as was reported 
in one human cell line before (Qi et al., 2003). We further 
show that HCC cells with enforced expression of NICD   
undergo cell cycle arrest in G2 and display increased apoptotic 
activity. The Notch pathway interacts with multiple molecu-
lar effectors, and there are probably multiple mechanisms in-
volved in inhibiting tumor cell progression. In the future, 
thorough investigation of Notch effectors should bring more 
mechanistic insights into HCC development.
Our findings suggest a model in which Notch signaling acts 
as a tumor suppressor feedback mechanism in response to acti-
vation of E2F transcription factors in TKO liver cells. Although 
this negative feedback is clearly not sufficient to prevent cancer 
initiation, activation of Notch may significantly slow the ex-
pansion of tumor cells in vivo, and we found that expression of 
a Notch pathway signature of 17 genes strongly predicts sur-
vival in HCC patients. Because signaling downstream of Notch1 
may  play  a  tumor-suppressor  role  in  different  cancer  types 
(Nicolas et al., 2003; Hanlon et al., 2010; Ranganathan et al., 
2011), our observations indicate that local activation of the 
Notch pathway may provide novel treatment approaches in a 
large group of human cancers of epithelial origin.
MATERIALS AND METHODS
Mice and tumor experiments. Rb family cTKO mice were described 
previously (Viatour et al., 2008) and were maintained in a mixed 129Sv/J; 
C57/BL6 background. For intrasplenic injections, mice were anesthetized 
and surgically opened on the upper left quadrant of the abdomen, followed 
by injection of adenovirus into the spleen. In Rosa26CreER TKO mice, Cre was 
induced by four consecutive injections of 1 mg Tam (T-5648; Sigma-Aldrich) 
in corn oil. Tam-injected Rosa26CreER TKO mice were euthanized and ana-
lyzed before their health deteriorated; although the exact cause of death in 
TKO mice is not known, it may be caused by metabolic and food absorption 
problems. Injections were performed in mice that were between 2 and 6 mo 
of age, most of the mice being 10–12 wk old. Rosa26LSL-YFP mice were obtained 
from the Jackson Laboratory (Gt(ROSA)26Sortm1(EYFP)Cos/J). Subcutaneous 
serial transplantation of cells was performed in SCID mice, obtained from the 
Stanford mouse colony. Limiting dilution transplantation experiments were 
tumor suppressor display different characteristics than pro-
genitor cells expanding in TKO mice (Benhamouche et al., 
2010). In addition, we found that some TKO liver progenitors 
are positive for markers that were originally developed in a 
model of DDC-induced liver progenitor expansion. How-
ever, the paucity of C3+, C7+, or E10+ cells in TKO mice 
compared with DDC treatment (compare Fig. 2 E with Fig. S2, 
L–N), as well as the lack of organized structure in TKO livers 
versus the formation of atypical bile ducts in the DDC model 
(Fig. S2, O and P) further suggest that the populations of pro-
genitor cells involved in the expansion in the two models are 
not equivalent. Nevertheless, the observation that some cells 
in early TKO lesions express Sox9 indicates that there are 
some similarities between the two systems. Future experi-
ments will continue to compare markers expressed by adult 
liver progenitor cells identified in different systems to better 
define distinct subpopulations of these cells.
In the TKO model, we found that the colony-forming 
potential was restricted to two distinct mutant stem/progeni-
tor cell populations in TKO mice, C3/C7/E10+ cells and 
Sca1+ cells. The decreased expression of Bmi1 and the in-
creased expression of lineage markers, as well as the increased 
cell cycle and colony-forming activities observed in TKO 
C3/C7/E10+ cells suggest that these cells may represent a 
more mature population of progenitors when compared with 
Sca1+ cells. C3/C7/E10+ or Sca1+ cells were not able to re-
capitulate tumors upon transplantation, suggesting that either 
they do not represent the cell of origin or that transplantation 
protocols need to be improved to allow a small number of 
purified stem/progenitor cells to colonize recipient liver.
Our data strongly suggest that TKO liver tumors arise 
from subpopulations of stem/progenitor cells. After exiting 
quiescence and an initial phase of expansion, these TKO cells 
undergo some differentiation, and these fairly differentiated 
proliferating cells represent the bulk of the HCC tumors. This 
model fits with increasing evidence suggesting that loss of RB 
function initiates cancer from specific populations of stem/
progenitor cells (Macpherson, 2008; Viatour et al., 2008; Calo 
et al., 2010; Choi et al., 2010; Jiang et al., 2010), providing a 
general model for tumor suppression by the RB pathway. 
However, we cannot formally exclude at this point that an 
intermediate cell population (i.e., very late progenitor or early 
hepatocyte) could also be the cell of origin in TKO HCC. 
The recent identification of Cre-expressing mouse strains in 
liver progenitor populations (Dorrell et al., 2011; Shin et al., 
2011) may provide novel means to perform lineage-tracing 
experiments and to formerly identify the cell of origin of the 
TKO tumors, including its differentiation potential and the 
role of the RB pathway in its cell fate.
Previous studies in neural progenitors have reported re-
pression of Notch signaling by p107 (Vanderluit et al., 2004, 
2007). In this study, we found that RB family members di-
rectly control the transcription of multiple components of the 
Notch  pathway  in  human  and  mouse  cells,  identifying  a 
strong link between these two central cellular pathways in 
liver cells. However, the lack of induction of Notch pathway JEM Vol. 208, No. 10 
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was detected with the Dual Reporter Assay System kit (Promega). Each ex-
periment was performed in triplicate, and three independent experiments 
were conducted. The RB reintroduction experiment was performed using a 
plasmid expressing a fusion protein between GFP and a large pocket frag-
ment of RB with mutations in seven CDK phosphorylation sites (GFP-
RB7LP [a gift of E.S. Knudsen, Thomas Jefferson University, Philadelphia, 
PA]; Jiao et al., 2006).
ChIP analysis. ChIP was performed as described previously (O’Geen et al., 
2006) with cultured hepatic TKO tumor cells. Antibodies used for immuno-
precipitations were as follows: E2F1 (sc-193X), E2F3 (sc-878X), E2F4   
(sc-1082X), and p16 (sc-467). Cyclin A, Notch1, Notch3, Notch4, Dtx3, Dtx4, 
and Jag2 promoter binding was assessed by quantitative PCR using SYBR 
green ER Master mix (Invitrogen).
RT-PCR and microarray analysis. RNA was extracted either from fro-
zen tumors or from cells sorted directly in TRIZOL. RNAs were processed, 
and qPCR reactions were prepared as described previously (Viatour et al., 
2008). Microarray data were normalized with Expression Console software 
(Affymetrix), using robust means analysis algorithms. Low signals (<50) were 
filtered out using the PreprocessDataset module in GenePattern (http://
www.broadinstitute.org/cancer/software/genepattern/).  Differentially  ex-
pressed genes in TKO mice were identified using SAM software (Tusher et al., 
2001) with the cutoff FDR of 5%. Array files are available on the GEO Data-
Sets database under accession no. GSE19004.
To compare TKO array (Affymetrix oligo) with mouse arrays from Lee 
et al. (2004), TKO data were collapsed to gene symbols and then converted 
to the format equivalent to two-color array by taking the log2 of expression 
ratio (TKO signal vs. mean of control signal). Log ratio data of genes present 
in both platforms were used in subsequent analysis. To further compare TKO 
arrays with human HCC microarrays (Lee et al., 2004; Boyault et al., 2007), 
we selected orthologous genes that were present in both arrays by using the 
mammalian orthology from the Mouse Genome Informatics database. In 
each tissue set, gene expression ratios were median centered for each gene. 
Hierarchical clustering (Eisen et al., 1998) was used to compare median-
centered array data, using Pearson correlation in sample distance measure. 
DAVID analysis was performed as described previously (Huang et al., 2008). 
GSEA (Subramanian et al., 2005) was performed using GSEA version 2.0 
software. Curated gene sets for GSEA analysis were obtained from http://
www.broadinstitute.org/gsea/msigdb/collections.jsp#C2. Enrichment is 
considered significant when the p-value is <0.05 and the FDR is <0.25.
For the survival analysis, RNA from 53 human HCCs was obtained 
from Caucasian and Chinese patients, representing survival group A and B 
HCC patients. The HCC samples were hybridized to Illumina bead chips 
HumanRef8v2 and analyzed according to the manufacturer’s recommenda-
tion. All human tissue samples were obtained with approval by the Institu-
tional Review Board of the National Institutes of Health and collaborating 
institutions on the condition that all samples were anonymized. The ability of 
the Notch family genes to predict overall survival of HCC patients were ana-
lyzed by retrieving the 17 genes in the Notch signature from the HCC data-
set.  Hierarchical  cluster  analysis  identified  two  clinically  relevant  distinct 
subgroups of human HCCs based on the 17-gene expression profile. Kaplan-
Meier plots and Mantel-Cox statistical analysis were applied in the survival 
analysis (Prism 5.01; GraphPad Software).
Flow cytometry. Single cell suspensions were stained with Annexin V 
(Roche) or antibodies against Ter119, CD45, and Sca1 (eBioscience), as 
well  as  unconjugated  antibodies  recognizing  oval  cells  (Dorrell  et  al., 
2008). Anti–rat PE (eBioscience) was used as a secondary antibody. All 
analysis  and  sorting  were  performed  as  described  previously  (Viatour   
et al., 2008).
Statistical analysis. Statistical significance was assayed by the two-tailed 
Student’s t test (*, P < 0.05; **, P < 0.01; ***, P < 0.005). Data are repre-
sented as mean ± SEM.
performed by injecting a 50:50 mix of cells/Matrigel (Invitrogen) into the 
flank of SCID/Il2r/ mice (The Jackson Laboratory). DAPT was solubi-
lized in corn oil and injected at a concentration of 10 mg/kg/d in the peri-
toneal cavity. All the experiments with mice were approved by Stanford 
Institutional Animal Care and Use Committee.
Histology, immunostaining, and immunoblot analysis. For paraffin 
sections, organs were fixed in 4% paraformaldehyde overnight at room tem-
perature and then transferred to 70% ethanol before processing and embed-
ding. For cryosections, organs were embedded and frozen in OCT using 
liquid nitrogen–cooled isopentane. For pathological analysis, paraffin sections 
were stained with hematoxylin and eosin (H&E). Tumor quantification was 
performed  with  the  BIOQUANT  Life  Science  software  (BIOQUANT   
Image Analysis Corp.). Antigen retrieval on paraffin sections was performed 
using the Trilogy solution (Cell Marque) for 15 min in a pressure cooker. 
Cryosections were thawed at room temperature for at least 20 min and fixed 
with 4% formaldehyde for 15 min. Sections labeled with C3, C7, and E10 
antibodies were fixed in 100% acetone at 20°C for 10 min. All sections 
were then in brief washed in PBS + 0.1% Tween 20 (PBST) and then blocked 
for 1 h at room temperature in PBST with 10% normal horse serum and 1% 
bovine serum Albumin. Sections were incubated with primary antibodies in 
block solution overnight at room temperature, washed in PBST, and then in-
cubated with secondary antibodies diluted 1:500 in block solution for 1 h at 
room temperature. Primary antibodies used were anti-Ki67 (BD), anti-CK19 
(Dako), anti-Albumin (Bethyl Laboratories, Inc.), anti-A6 (a gift from V. Fac-
tor, National Cancer Institute, National Institutes of Health, Bethesda, MD), 
anti-Sca1 (eBioscience), anti-EpCAM (BD), anti-GS (BD), and rat antibodies 
marking oval cells (Dorrell et al., 2008). Immunohistochemistry for Notch 
pathway components was performed as described previously (Mazur et al., 
2010a,b) using antibodies recognizing active Notch1 (Abcam), Notch2   
(Development Studies Hybridoma Bank), and HES1 (gift from T. Sudo, Toray 
Industries, Inc., Kamakura, Japan). Protein expression was analyzed by immuno-
blotting, as described previously (Ho et al., 2009). Primary antibodies used 
were  anti-GAPDH  (Santa  Cruz  Biotechnology,  Inc.)  and  anti–cleaved 
Notch1 (Cell Signaling Technology).
Cell preparation and culture. To obtain single cell suspensions, livers were 
first perfused with a mixture of 1 mg/ml Collagenase A/D and 1 mg/ml 
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